1. Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors
- Author
-
Bethany Rebekah Hill, Meryem Ozgencil, Lauryn Buckley-Benbow, Sophie Louise Pamela Skingsley, Danielle Tomlinson, Carmen Ortueta Eizmendi, Alessandro Agnarelli, and Roberto Bellelli
- Subjects
CP: Molecular biology ,CP: Cancer ,Biology (General) ,QH301-705.5 - Abstract
Summary: The advent of PARP inhibitors (PARPis) has profoundly changed the treatment landscape of BRCA1/BRCA2-mutated cancers. Despite this, the development of resistance to these compounds has become a major challenge. Hence, a detailed understanding of the mechanisms underlying PARPi sensitivity is crucially needed. Here, we show that loss of the POLE3-POLE4 subunits of DNA polymerase epsilon (Polε) strongly sensitizes cancer cells to PARPis in a Polε level-independent manner. Loss of POLE3-POLE4 is not associated with defective RAD51 foci formation, excluding a major defect in homologous recombination. On the contrary, treatment with PARPis triggers replicative gap accumulation in POLE3-POLE4 knockout (KO) cells in a PRIMPOL-dependent manner. In addition to this, the loss of POLE3-POLE4 further sensitizes BRCA1-silenced cells to PARPis. Importantly, the knockdown of 53BP1 does not rescue PARPi sensitivity in POLE3-POLE4 KO cells, bypassing a common PARPi resistance mechanism and outlining a potential strategy to sensitize cancer cells to PARPis.
- Published
- 2024
- Full Text
- View/download PDF